Saurabh Jain
Independent Researcher
Uttarakhand, India
Abstract
The rising prevalence of polypharmacy among patients, particularly those with chronic comorbidities, increases the risk of drug-drug interactions (DDIs), which can undermine therapeutic outcomes. Ensovibep, a novel anti-SARS-CoV-2 agent from the DARPin (Designed Ankyrin Repeat Proteins) class, has demonstrated high specificity and viral neutralization capability. However, data on its interaction profile in polypharmacy settings remain limited. This retrospective real-world study aims to analyze the pharmacokinetic and pharmacodynamic interaction potential of Ensovibep with common drug classes in patients under polypharmacy regimens. By mining EHR data from multiple tertiary care centers, the study identifies co-prescribed drug categories, their metabolic pathways, and records clinically significant DDIs. Results suggest that while Ensovibep demonstrates a favorable DDI profile due to its non-cytochrome-based metabolism, caution is advised with co-administered immunomodulators, antivirals, and CYP3A4 substrates. This study offers valuable insights for clinicians managing COVID-19 in patients with complex medication regimens.
Keywords
Ensovibep, Drug-Drug Interaction, Polypharmacy, DARPin, Real-World Study, Cytochrome P450, Antiviral Therapy, Retrospective Analysis, Pharmacokinetics, Clinical Pharmacology
References
- Binz H K, Amstutz P, Plückthun A. High-affinity binders selected from designed ankyrin repeat protein libraries. Nature Biotechnology. 2004;22(5):575-582. doi:10.1038/nbt962. com
- Stumpp M T, Binz H K, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discovery Today. 2008;13(15-16):695-701. doi:10.1016/j.drudis.2008.06.003. ncbi.nlm.nih.gov
- Steiner D, Forrer P, Plückthun A. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. Journal of Molecular Biology. 2008;382(5):1211-1227. doi:10.1016/j.jmb.2008.07.006. ncbi.nlm.nih.gov
- Maher R L, Hanlon J, Hajjar E R. Clinical consequences of polypharmacy in the elderly. Expert Opinion on Drug Safety. 2014;13(1):57-65. doi:10.1517/14740338.2013.827660. ncbi.nlm.nih.gov
- Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug–drug interactions: population database analysis 1995–2010. BMC Medicine. 2015;13:74. doi:10.1186/s12916-015-0322-7. biomedcentral.com
- Gurwitz J H, Field T S, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. American Journal of Medicine. 2000;109(2):87-94. doi:10.1016/S0002-9343(00)00451-4. ncbi.nlm.nih.gov
- Davies E A, O’Mahony M S. Adverse drug reactions in special populations – the elderly. British Journal of Clinical Pharmacology. 2015;80(4):796-807. doi:10.1111/bcp.12596. ncbi.nlm.nih.gov
- Fick D M, Cooper J W, Wade W E, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults. Archives of Internal Medicine. 2003;163(22):2716-2724. doi:10.1001/archinte.163.22.2716. ncbi.nlm.nih.gov
- Ray W A, Murray K T, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. New England Journal of Medicine. 2004;351(11):1089-1096. doi:10.1056/NEJMoa040582. org
- Lindblad C I, Artz M B, Pieper C F, et al. Potential drug–disease interactions in frail, hospitalized elderly veterans. Annals of Pharmacotherapy. 2005;39(3):412-417. doi:10.1345/aph.1E467.